Maravai LifeSciences Holdings Valuation
Is MRVI * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MRVI * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRVI * (MX$85) is trading above our estimate of fair value (MX$81.05)
Significantly Below Fair Value: MRVI * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRVI *?
Other financial metrics that can be useful for relative valuation.
What is MRVI *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$2.10b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 5.2x |
Enterprise Value/EBITDA | 140.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does MRVI *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 13.6x | ||
LAB B Genomma Lab Internacional. de | 1x | 8.2% | Mex$15.9b |
FTRE Fortrea Holdings | 0.7x | 2.8% | US$2.0b |
A141080 LigaChem Biosciences | 45.5x | 22.9% | ₩2.6t |
688114 MGI Tech | 7.2x | 16.7% | CN¥20.4b |
MRVI * Maravai LifeSciences Holdings | 3.8x | 5.3% | Mex$2.1b |
Price-To-Sales vs Peers: MRVI * is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (5.3x).
Price to Earnings Ratio vs Industry
How does MRVI *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Sales vs Industry: MRVI * is good value based on its Price-To-Sales Ratio (3.8x) compared to the Global Life Sciences industry average (4.2x).
Price to Sales Ratio vs Fair Ratio
What is MRVI *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.8x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate MRVI *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.